Welcome to the NINLARO Co-Pay Assistance Program, a service of NINLARO 1Point. Eligible patients may pay as little as $25 for their NINLARO prescription, up to $25,000 a year.

Please be aware that the information you provide will be used by companies working with Takeda Oncology for the purposes of evaluating and continually confirming your eligibility for the NINLARO Co-Pay Assistance Program. In addition, Takeda Oncology, and companies working with Takeda Oncology, will have access to the information you provide and the information that is obtained through your use of the co-pay card during your participation in this program and other optional programs you sign up for. Please review Takeda Oncology's privacy policy available here.

*Required field.

*First Name

*Last Name

*Street Address – Line 1

Street Address – Line 2



*ZIP Code

*Date of Birth

Email Address

Confirm Email Address

*Phone Number


Opt-in for additional programs.

*I am interested in learning more about programs that provide personalized education and support for people who are taking NINLARO and would like to be contacted further by Takeda Oncology or its third parties.

*Takeda Oncology, its affiliates, service providers, and co-promotion partners would like to occasionally send you product and disease-state information. Do you give permission to use your personal information for these purposes?

You may revoke your permission at any time by contacting the NINLARO Co-Pay Assistance Program at 1-855-902-6725, 8 AM-8 PM ET, Monday through Friday.

Program participants who meet all Program eligibility requirements will pay the first Twenty-five Dollars ($25.00) of their co-pay amount and Takeda will pay the remaining co-pay or co-insurance for each NINLARO® (ixazomib) prescription, up to a maximum of Twenty-five Thousand Dollars ($25,000.00) annually per patient. Program participants will be responsible for any remaining co-pay or co-insurance balance for each prescription. Eligible patients will be eligible for the co-pay assistance up to the maximum amount for a period of twelve (12) months, which begins when a patient enrolls and ends twelve (12) months later. Patients must re-enroll every twelve (12) months in order to maintain eligibility. Restrictions may apply.